phenytoin has been researched along with Hyperammonemia in 7 studies
Hyperammonemia: Elevated level of AMMONIA in the blood. It is a sign of defective CATABOLISM of AMINO ACIDS or ammonia to UREA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valproic acid (VPA), which is widely used to treat epilepsy, migraine, and bipolar disorder, can causes severe hyperammonemia." | 7.81 | Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy. ( Hirai, K; Imai, K; Inoue, K; Inoue, Y; Itoh, K; Suzuki, E; Takahashi, T; Takahashi, Y; Tsuji, D; Yamamoto, Y, 2015) |
| "Valproic acid, which is widely used to treat various types of epilepsy, may cause severe hyperammonemia." | 7.80 | 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy. ( Hayashi, H; Imai, K; Inoue, K; Inoue, Y; Itoh, K; Miyakawa, K; Suzuki, E; Takahashi, T; Takahashi, Y; Tsuji, D; Yamamoto, Y; Yazawa, R, 2014) |
| "We present a case of a 29-year-old female with a history of epilepsy who was admitted for convulsive status epilepticus (CSE), which was controlled by intravenous VPA, as well as oral VPA and phenytoin." | 4.31 | Valproate-related hyperammonemic encephalopathy with generalized suppression EEG: a case report. ( Liu, X; Peng, X, 2023) |
| "Valproic acid (VPA), which is widely used to treat epilepsy, migraine, and bipolar disorder, can causes severe hyperammonemia." | 3.81 | Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy. ( Hirai, K; Imai, K; Inoue, K; Inoue, Y; Itoh, K; Suzuki, E; Takahashi, T; Takahashi, Y; Tsuji, D; Yamamoto, Y, 2015) |
| "Valproic acid, which is widely used to treat various types of epilepsy, may cause severe hyperammonemia." | 3.80 | 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy. ( Hayashi, H; Imai, K; Inoue, K; Inoue, Y; Itoh, K; Miyakawa, K; Suzuki, E; Takahashi, T; Takahashi, Y; Tsuji, D; Yamamoto, Y; Yazawa, R, 2014) |
| "Hyperammonemia was defined as a plasma ammonia level exceeding 100 μg/dl with reference to the standard range and previous reports." | 1.39 | Risk factors for hyperammonemia in pediatric patients with epilepsy. ( Imai, K; Inoue, K; Inoue, Y; Itoh, K; Kagawa, Y; Mishima, N; Takahashi, Y; Yamamoto, Y; Yazawa, R, 2013) |
| "Transient hyperammonemia was noted." | 1.35 | Postictal transient hyperammonemia. ( Liu, KT; Su, CS, 2008) |
| "To describe the dose-concentration relationship of a continuous intravenous infusion of valproic acid (VPA) in pediatric patients when a dosing protocol is used." | 1.34 | Clinical utility of a continuous intravenous infusion of valproic acid in pediatric patients. ( Baumann, RJ; Cook, AM; Farzam, F; Kuhn, RJ; Lewis, DA; Taylor, LM, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, X | 1 |
| Peng, X | 1 |
| Yamamoto, Y | 3 |
| Takahashi, Y | 3 |
| Imai, K | 3 |
| Mishima, N | 1 |
| Yazawa, R | 2 |
| Inoue, K | 3 |
| Itoh, K | 3 |
| Kagawa, Y | 1 |
| Inoue, Y | 3 |
| Suzuki, E | 2 |
| Takahashi, T | 2 |
| Miyakawa, K | 1 |
| Tsuji, D | 2 |
| Hayashi, H | 1 |
| Hirai, K | 1 |
| Taylor, LM | 1 |
| Farzam, F | 1 |
| Cook, AM | 1 |
| Lewis, DA | 1 |
| Baumann, RJ | 1 |
| Kuhn, RJ | 1 |
| Velioğlu, SK | 1 |
| Gazioğlu, S | 1 |
| Liu, KT | 1 |
| Su, CS | 1 |
7 other studies available for phenytoin and Hyperammonemia
| Article | Year |
|---|---|
Valproate-related hyperammonemic encephalopathy with generalized suppression EEG: a case report.
Topics: Adult; Anticonvulsants; Brain Diseases; Electroencephalography; Epilepsy; Female; Humans; Hyperammon | 2023 |
Risk factors for hyperammonemia in pediatric patients with epilepsy.
Topics: Acetazolamide; Adolescent; Age Factors; Anticonvulsants; Child; Child, Preschool; Dose-Response Rela | 2013 |
4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy.
Topics: Alleles; Amino-Acid N-Acetyltransferase; Ammonia; Anticonvulsants; Asian People; Biomarkers, Pharmac | 2014 |
Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
Topics: Adolescent; Ammonia; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Genotype; Glutamate | 2015 |
Clinical utility of a continuous intravenous infusion of valproic acid in pediatric patients.
Topics: Administration, Oral; Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combinatio | 2007 |
Non-convulsive status epilepticus secondary to valproic acid-induced hyperammonemic encephalopathy.
Topics: Adult; Ammonia; Anticonvulsants; Brain; Electroencephalography; Hepatic Encephalopathy; Humans; Hype | 2007 |
Postictal transient hyperammonemia.
Topics: Adult; Anticonvulsants; Epilepsy, Tonic-Clonic; Humans; Hyperammonemia; Liver Function Tests; Male; | 2008 |